Denali Therapeutics Inc. Assets, Fair Value Disclosure
Denali Therapeutics Inc. (DNLI) had Assets, Fair Value Disclosure of $886.50 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AssetsFairValueDisclosure · last filed 2026-08-06
- 2026-06-30: Assets, Fair Value Disclosure $886.50M.
- 2026-03-31: Assets, Fair Value Disclosure $744.99M.
- 2025-12-31: Assets, Fair Value Disclosure $935.65M.
- 2025-09-30: Assets, Fair Value Disclosure $807.59M.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $886.50M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $744.99M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $935.65M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $807.59M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $945.25M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $1.04B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.14B 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.27B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.33B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.41B 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.03B 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.06B 10-Q · filed 2023-11-07 |
| 2023-06-30 | $1.17B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $1.26B 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.28B 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.09B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.10B 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.20B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.26B 10-K · filed 2023-02-27 |
| 2021-09-30 | $1.34B 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.38B 10-Q · filed 2021-08-04 |
| 2021-03-31 | $1.44B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.48B 10-K · filed 2022-02-28 |
| 2020-09-30 | $957.24M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $530.83M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $569.55M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $446.03M 10-K · filed 2021-02-26 |
| 2019-09-30 | $473.76M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $507.69M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $568.33M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $588.77M 10-K · filed 2020-02-27 |
| 2018-09-30 | $501.01M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $534.75M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $585.02M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $461.47M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |